ClinicalTrials.gg
CompletedNCT03673995Updated Jun 16, 2020

Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS

An interventional study of Myo-inositol+L-tyrosine in Polycystic Ovary Syndrome, Menstrual Problem and Hirsutism, sponsored by Pharmarte srl. Completed at 1 site in Italy. Open to female participants aged 16 Years to 38 Years. Per ClinicalTrials.gov, last updated 2020-06-16.

Sponsored by Pharmarte srl · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled May 2017, registered Aug 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
186
Allocation
Not applicable
Ages
16 Years to 38 Years
Sex
Female
01

Study summary

PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal evaluation , hirsutism scoring and ovulation assesment. Most of them during the treatment improved their symptoms.

02

Conditions studied

  • Polycystic Ovary Syndrome
  • Menstrual Problem
  • Hirsutism
03

In context

Polycystic Ovary Syndrome

956 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

This study's enrollment of 186 is above the median of 70 across 697 interventional studies indexed under Polycystic Ovary Syndrome.

Browse Polycystic Ovary Syndrome studies →

Lead sponsor

This is the only study on the registry with Pharmarte srl as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 38 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

° PCOS patients

Exclusion criteria

Exclusion Criteria:

  • thyroid dysfunction
  • hyperprolactinemia
  • adrenal hyperplasia
  • patients taking oral
  • any other endocrinological pathologies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    Myo-inositol+L-tyrosine

    One sachet per day containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid for improving PCOS symptoms.

    Dietary Supplement: Myo-inositol+L-tyrosine

Interventions

  • Dietary supplementMyo-inositol+L-tyrosine

    Drug pages: Inositol · Tyrosine

    PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.

06

What researchers measure

Primary outcomes

  1. Restore of regular menstrual period

    Self report

    Time frame: 6 months of treatment

Secondary outcomes

  1. Improving hirsutism

    Standardised visual scales are preferred when assessing hirsutism, such as the modified Ferriman Gallwey score (mFG) with a level ≥ 4 - 6 indicating hirsutism,

    Time frame: 6 months of treatment

  2. Restore ovulation

    Progesterone value in luteal phase

    Time frame: 6 months of treatment

07

Study locations

1 site
  • Altamedica Reproductive Medicine
    Roma, 00198, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Aug 2018, 15 months.

Of 217 interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 39. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2018
First posted
Sep 17, 2018
StartActual
May 2, 2017
Primary completionActual
Aug 22, 2018
CompletionActual
Oct 30, 2018
Last update
Jun 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03673995
Lead sponsor
Pharmarte srl
Responsible party
Sponsor
First posted
Sep 17, 2018
Start date
May 2, 2017
Primary completion
Aug 22, 2018
Completion
Oct 30, 2018
Last update
Jun 16, 2020

Study contacts

Mario Montanino Oliva, M.D.
principal investigator · Altamedica Reproductive Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Inositol · Tyrosine

Start the discussion